Tackling the enormous global burden of anaemia The Lancet Haematology

https://www.thelancet.com/journals/lanhae/home?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz-9UNhgUP3ln5jSUkU0IJ8DLeGvYdz3AZewDITBHJ6yRYInyrbKypqaCjRL6yn8rXNJ14eLphQz8VB83yE1LGGkc_6KDSw&utm_content=272339749&utm_source=hs_automation Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission https://www.thelancet.com/commissions/sickle-cell-disease?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz-_crY8AfrB3gaPdFyE8oCcNwDwVvklMrbOVLAM6CaJtowC-wNYAUhyLkc8EBA12HRl9Fhg8bZB36Q41NBb_VUZHLQ3A3w&utm_content=272339749&utm_source=hs_automation Prevalence, years lived with disability, and trends in anaemia burden by severity and cause, 1990–2021: findings from the Global Burden of Disease Study 2021 Open Access https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00160-6/fulltext?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz--dyn5MIuVa3qHweFBByHVBdRKy1CTQOxUWFPNCNsONQF1r1TtnJ6159RTUyOlPTmWz8yZwCKy7mRfbQUY1nOcTEb6cyg&utm_content=272339749&utm_source=hs_automation Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the Global Burden of Disease Study 2021 Open Access https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(23)00118-7/fulltext?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz-8tjc4D5rJHwZp1DR3gFwH-lGFGxqB0krMLCsjr7pR6J6dNGZ5hSKLqb9mc5jJqgM90LL89g-ffRa2WvIKkY4RL9c8U9Q&utm_content=272339749&utm_source=hs_automation Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial Open Access https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00040-0/fulltext?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz-8rMG9wO5J1BMLuSSMe8l9l1tvK7HoTQu9RGAABC1j2qiYWqhL4R-xE81AW0Jr1uB6ZliBNDsSa3fRnRDmZ8iZuaWmgGA&utm_content=272339749&utm_source=hs_automation Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00072-2/fulltext?dgcid=hubspot_email_jcr23_lanhae&utm_campaign=jcr23&utm_medium=email&_hsmi=272339749&_hsenc=p2ANqtz-8oJZaw7vC8aZKB2tIMzDyUC6SzM5tSf46RtR217fJMK4yZWWrcg5y_bvbUUk2VXG7iL81IkZpGPD9K9mIAMDSK3Jatqg&utm_content=272339749&utm_source=hs_automation